|Bid||38.40 x 1000|
|Ask||38.50 x 3000|
|Day's Range||38.16 - 38.62|
|52 Week Range||27.88 - 40.97|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||15.22|
|Earnings Date||Oct. 27, 2020 - Nov. 02, 2020|
|Forward Dividend & Yield||1.52 (3.97%)|
|Ex-Dividend Date||Jul. 30, 2020|
|1y Target Est||41.85|
New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.
Gilead is aiming to make enough of the drug by the end of the year to treat more than 2 million COVID-19 patients, and agreed to send nearly all of its remdesivir supply to the United States through September. There are also fears of shortages outside the United States, and separately on Friday, Britain's Hikma Pharmaceuticals Plc said it has started manufacturing remdesivir at its Portugal plant.
Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.